文献速递MDS 与骨髓增殖性肿瘤

骨髓增生异常综合征:2021年诊断、危险分层与管理更新

Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management.
PubMed 文献 · Am J Hematol · 2020-01-01

骨髓增生异常综合征(MDS)是一组异质性髓系肿瘤,表现为外周血细胞减少和向急性髓系白血病转化风险增高。诊断基于骨髓涂片和活检的形态学病态造血证据,结合核型、流式细胞术和分子遗传学辅助。危险分层常用修订版国际预后评分系统(IPSS-R),治疗按风险、输血需求、骨髓原始细胞比例、细胞遗传学和突变特征、合并症、异基因干细胞移植可能性和既往低甲基化药物暴露选择;2020年获批新药包括luspatercept和口服HMA ASTX727。

要点

  • MDS诊断基于骨髓涂片和活检形态学病态造血证据,核型、流式细胞术和分子遗传学通常为补充。
  • 最常用的预后评分系统为修订版国际预后评分系统(IPSS-R),体细胞突变有助于定义预后和治疗。
  • 低危MDS治疗目标是减少输血需求、降低向高危疾病或AML转化并改善生存;高危MDS目标是延长生存。

核心结论

  • MDS是一组异质性髓系肿瘤,表现为外周血细胞减少和向急性髓系白血病转化风险增高,多见于老年男性和既往暴露于细胞毒治疗者。
  • 治疗按风险、输血需求、骨髓原始细胞百分比、细胞遗传学和突变特征、合并症、异基因干细胞移植可能性和既往低甲基化药物暴露选择。
  • 目前尚无获批的干预措施用于进展性或难治性疾病,尤其在接受低甲基化药物治疗后;选项包括参加临床试验、阿糖胞苷为基础的治疗或异基因干细胞移植。

研究设计与样本

  • 本文为综述,汇总MDS的诊断、危险分层和管理更新。

主要发现

  • 2020年新药和试验性方法大量涌现,2020年获批的新药为luspatercept和口服低甲基化药物ASTX727。
  • 当前可用治疗包括生长因子支持、来那度胺、低甲基化药物、强化化疗和异基因干细胞移植。

关键数值与推荐

  • 诊断基于骨髓涂片和活检形态学病态造血证据,核型、流式细胞术和分子遗传学信息通常为补充并可能帮助细化诊断。
  • 最常用的预后评分系统为修订版国际预后评分系统(IPSS-R),所有评分系统一般包括外周血细胞减少、骨髓原始细胞百分比和细胞遗传学特征分析。
  • 体细胞突变有助于定义预后和治疗。

临床怎么用

  • 低危MDS治疗目标是减少输血需求、降低向高危疾病或AML转化并改善生存。
  • 高危MDS治疗目标是延长生存。
  • 进展性或难治性疾病尤其低甲基化药物治疗后,选项包括参加临床试验、阿糖胞苷为基础的治疗或异基因干细胞移植。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DISEASE OVERVIEW: The myelodysplastic syndromes (MDS) are a very heterogeneous group of myeloid disorders characterized by peripheral blood cytopenias and increased risk of transformation to acute myelogenous leukemia (AML). Myelodysplastic syndromes occur more frequently in older males and in individuals with prior exposure to cytotoxic therapy. DIAGNOSIS: Diagnosis of MDS is based on morphological evidence of dysplasia upon visual examination of a bone marrow aspirate and biopsy. Information obtained from additional studies such as karyotype, flow cytometry and molecular genetics is usually complementary and may help refine diagnosis. RISK-STRATIFICATION: Prognosis of patients with MDS can be calculated using a number of scoring systems. In general, all these scoring systems include analysis of peripheral cytopenias, percentage of blasts in the bone marrow and cytogenetic characteristics. The most commonly accepted system is the Revised International Prognostic Scoring System (IPSS-R). Somatic mutations can help define prognosis and therapy. RISK-ADAPTED THERAPY: Therapy is selected based on risk, transfusion needs, percent of bone marrow blasts, cytogenetic and mutational profiles, comorbidities, potential for allogeneic stem cell transplantation (alloSCT) and prior exposure to hypomethylating agents (HMA). Goals of therapy are different in lower-risk patients than in higher-risk individuals and in those with HMA failure. In lower-risk MDS, the goal is to decrease transfusion needs and transformation to higher risk disease or AML, as well as to improve survival. In higher-risk disease, the goal is to prolong survival. In 2020, we witnessed an explosion of new agents and investigational approaches. Current available therapies include growth factor support, lenalidomide, HMAs, intensive chemotherapy and alloSCT. Novel therapeutics approved in 2020 are luspatercept and the oral HMA ASTX727. At the present time, there are no approved interventions for patients with progressive or refractory disease particularly after HMA-based therapy. Options include participation in a clinical trial, cytarabine-based therapy or alloSCT.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Garcia-Manero G, Chien KS, Montalban-Bravo G, et al. Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management. Am J Hematol. 2020. PMID: 32744763. doi:10.1002/ajh.25950

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。